Alnylam Pharmaceuticals, Inc. (ALNY)

US — Healthcare Sector
Peers: PRQR  WVE  BPMC  APLS  INCY  UTHR  RARE  BMRN  SGEN  EXEL  HALO  KRYS  MDGL  RETA  ISEE  AMLX  KRTX  DAWN 

Automate Your Wheel Strategy on ALNY

With Tiblio's Option Bot, you can configure your own wheel strategy including ALNY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol ALNY
  • Rev/Share 18.1074
  • Book/Share 0.8902
  • PB 342.133
  • Debt/Equity 11.2759
  • CurrentRatio 3.0385
  • ROIC -0.0279

 

  • MktCap 39710969280.0
  • FreeCF/Share -0.5813
  • PFCF -526.7755
  • PE -146.4367
  • Debt/Assets 0.3089
  • DivYield 0
  • ROE -5.0933

 

  • Rating C-
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 4
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation ALNY Redburn Atlantic -- Buy -- $353 March 31, 2025
Upgrade ALNY JP Morgan Neutral Overweight $280 $328 March 24, 2025
Initiation ALNY Scotiabank -- Sector Outperform -- -- Oct. 16, 2024
Upgrade ALNY Goldman Neutral Buy $198 $370 Aug. 16, 2024

News

Alnylam to Webcast Presentation at BofA Securities 2025 Health Care Conference
ALNY
Published: May 05, 2025 by: Business Wire
Sentiment: Neutral

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the BofA Securities 2025 Health Care Conference on Wednesday, May 14, 2025 at 11:20 am PT (2:20 pm ET). A live audio webcast of the presentation will be available on the Investors section of the Company's website, www.alnylam.com/events. A replay will be available on the Alnylam website within 48 hours after th.

Read More
image for news Alnylam to Webcast Presentation at BofA Securities 2025 Health Care Conference
Alnylam Q1 Earnings Beat Estimates, Product Revenues Rise Y/Y
ALNY
Published: May 02, 2025 by: Zacks Investment Research
Sentiment: Positive

ALNY reports better-than-expected first-quarter results as both earnings and revenues beat estimates, driven by higher product sales.

Read More
image for news Alnylam Q1 Earnings Beat Estimates, Product Revenues Rise Y/Y
Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2025 Earnings Call Transcript
ALNY
Published: May 01, 2025 by: Seeking Alpha
Sentiment: Neutral

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY ) Q1 2025 Earnings Conference Call May 1, 2025 8:30 AM ET Company Participants Christine Lindenboom – Chief Corporate Communications Officer Yvonne Greenstreet – Chief Executive Officer Tolga Tanguler – Chief Commercial Officer Pushkal Garg – Chief Medical Officer Jeff Poulton – Chief Financial Officer Conference Call Participants Tazeen Ahmad – Bank of America Gena Wang – Barclays Teraesa Vitelli – Scotiabank Ellie Merle – UBS Gary Nachman – Raymond James Ritu Baral – TD Cowen Kostas Biliouris – BMO Capital Markets Luca Issi – RBC Capital Markets Paul Matteis – Stifel Mike Ulz – Morgan …

Read More
image for news Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2025 Earnings Call Transcript
Compared to Estimates, Alnylam (ALNY) Q1 Earnings: A Look at Key Metrics
ALNY
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Neutral

While the top- and bottom-line numbers for Alnylam (ALNY) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Read More
image for news Compared to Estimates, Alnylam (ALNY) Q1 Earnings: A Look at Key Metrics
Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy
ALNY
Published: April 28, 2025 by: Business Wire
Sentiment: Neutral

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of its RNAi therapeutic vutrisiran for the treatment of wild type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM). ATTR-CM is a debilitating, rapidly.

Read More
image for news Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy
Alnylam Pharmaceuticals Presents 'Convincing Multi-Billion Dollar Opportunity': Analyst Upgrades Stock
ALNY
Published: March 24, 2025 by: Benzinga
Sentiment: Positive

The U.S. Food and Drug Administration on Thursday approved Alnylam Pharmaceuticals Inc.'s ALNY supplemental application for Amvuttra (vutrisiran).

Read More
image for news Alnylam Pharmaceuticals Presents 'Convincing Multi-Billion Dollar Opportunity': Analyst Upgrades Stock
Alnylam (ALNY) Surges 11.8%: Is This an Indication of Further Gains?
ALNY
Published: March 24, 2025 by: Zacks Investment Research
Sentiment: Positive

Alnylam (ALNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Read More
image for news Alnylam (ALNY) Surges 11.8%: Is This an Indication of Further Gains?
Alnylam Gets FDA Nod for Expanded Use of Amvuttra in Cardiomyopathy
ALNY
Published: March 21, 2025 by: Zacks Investment Research
Sentiment: Positive

ALNY secures FDA approval for an sNDA in the United States, seeking the label expansion of Amvuttra to treat ATTR amyloidosis with cardiomyopathy.

Read More
image for news Alnylam Gets FDA Nod for Expanded Use of Amvuttra in Cardiomyopathy
Alnylam Q4 Earnings Beat Estimates, Product Revenues Rise Y/Y
ALNY
Published: February 14, 2025 by: Zacks Investment Research
Sentiment: Positive

ALNY reports better-than-expected fourth-quarter results as both earnings and revenues beat estimates driven by higher product sales.

Read More
image for news Alnylam Q4 Earnings Beat Estimates, Product Revenues Rise Y/Y
Alnylam: Waiting For Regulatory Updates In March
ALNY
Published: February 13, 2025 by: Seeking Alpha
Sentiment: Positive

Alnylam's Amvuttra and partner Sanofi's fitusiran have PDUFA dates with the FDA next month, and approvals should create new revenue sources for the company. Alnylam's 2025 guidance for the TTR franchise implies modest growth acceleration compared to 2024, driven by Amvuttra's expected approval next month. Fitusiran's approval could result in meaningful annual royalties for Alnylam from partner Sanofi, enhancing long-term profitability and cash flows.

Read More
image for news Alnylam: Waiting For Regulatory Updates In March
ILMN vs. ALNY: Which Stock Is the Better Value Option?
ALNY, ILMN
Published: February 11, 2025 by: Zacks Investment Research
Sentiment: Neutral

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Illumina (ILMN) and Alnylam Pharmaceuticals (ALNY). But which of these two stocks offers value investors a better bang for their buck right now?

Read More
image for news ILMN vs. ALNY: Which Stock Is the Better Value Option?
Will These 5 Biotech Bigwig Stocks Surpass Q4 Earnings Forecast?
ALNY, BIIB, GILD, MRNA, VRTX
Published: February 10, 2025 by: Zacks Investment Research
Sentiment: Positive

We focus on biotech stocks like VRTX, GILD, BIIB, ALNY and MRNA, which are scheduled to report this week.

Read More
image for news Will These 5 Biotech Bigwig Stocks Surpass Q4 Earnings Forecast?

About Alnylam Pharmaceuticals, Inc. (ALNY)

  • IPO Date 2004-06-01
  • Website https://www.alnylam.com
  • Industry Biotechnology
  • CEO Dr. Yvonne L. Greenstreet M.B.A., M.D.
  • Employees 2230

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.